日期： 2026 年 9 月 21 日, 星期一
时间： 9:00 AM – 4:30 PM
地点： Cambridge Innovation Center (CIC), 1 Broadway, 5th Floor, Havana Room | Cambridge, MA
Prepare your strategy. Strengthen your story. Maximize your impact at RESI 2026 & JPM Healthcare 2027.
As you prepare for RESI 2026 & JPM 2027, the question isn’t just who you’ll meet, it’s whether your data, your strategy, and your story will stand up to investor scrutiny.
Certara’s Biotech Forum is a strategic workshop designed for biotech executives, founders, and investors who want to sharpen their development plan, de-risk their program, and enter RESI & JPM 2027 meetings with clarity and confidence. This forum is held in partnership with Life Science Nation (LSN), the organizers of RESI, giving you a direct line into how investors at RESI actually evaluate opportunities, straight from the source.
In a single focused day, we’ll address the early-stage decisions that most often derail promising programs and show you how to avoid them before you step into critical partnering and investor conversations, including a dedicated session on how to prepare for, run, and follow up on your RESI and JPM meetings themselves.
Submit your request to register
议程
What it takes to walk into RESI & JPM with a program that holds up to investor scrutiny, from science to story.
Learn what investors really look for in a pitch: a well-defined medical need, genuine differentiation, and the regulatory and commercial foresight to back it up.
Get a clear-eyed view of today’s regulatory landscape and how to build a realistic path from IND to first-in-human that also satisfies investors and partners.
Understand what “investor-ready” evidence looks like, from translational relevance to study design to manufacturability and how it translates into value-driving milestones.
Secure your spot for one-on-one sessions with Certara experts and connect with peers over lunch.
Moderated panel featuring LSN’s perspective, as organizers of RESI on the factor’s investors weigh beyond the science.
A forward-looking conversation on how recent regulatory shifts are changing the way companies need to think and plan earlier in development, with a look at where the real opportunities are right now.
The practical, tactical piece – how to prepare before the conference, run productive meetings during it, and convert conversations into real momentum after it ends.
Hear from biotech leaders, investors, pharma, and Certara experts on how early strategic decisions shape risk, speed, and fundability.
Recap key insights and learn how to continue the conversation with Certara’s experts.
Join interactive breakout tables with Certara and LSN experts covering every theme from the day – from regulatory strategy to RESI/JPM prep – to explore solutions for your specific challenges
Fran Brown, PhD
Senior Vice President, Global Head, Drug Development Science从药物早期发现到报批和上市后，Fran 在全球战略性和运营性药物开发方面拥有超过 25 年的经验。她在战略性药物发现和开发方面拥有广泛的知识，尤其侧重于发展策略和模型引导的药物开发 (MIDD) 的应用。
Maximilian Vargas, PhD, MBA
Vice President, Evidence & Access StrategyMax brings both scientific training and experience in healthcare product development that are important for evidence-based value and access strategies for pipeline and marketed products. Leading a team of analysts and focusing on projects involving late stage, launch, and due diligence efforts, Max’ experience cuts across all major therapeutic areas and care settings with special emphasis on CV / metabolic, oncology, gene therapies, ophthalmology, GI, and dermatology. Max and team have designed successful pricing and contracting strategies for products at launch and throughout the life cycle. He also leads projects focusing on managed markets communications strategies.
Submit your request to register
精选推荐
From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.
